A publication discussing CJC-1295 appeared in JBJS Reviews on May 20, 2026. The article, titled "Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications," is a structured narrative review.
The review addresses evidence, safety, and antidoping implications related to injectable peptides used in sports medicine settings. CJC-1295 is referenced within this broader review of injectable peptides.
This entry reflects the publication of the review itself. No specific findings, conclusions, or data points from the review have been detailed in the available event information. The review's title indicates a focus on evidence review, safety considerations, and antidoping regulatory implications for peptides within sports medicine.
CJC-1295 remains classified as an unapproved compound intended for research use only. It is not approved for human therapeutic use by regulatory authorities.
Readers interested in this publication can access the full review through the PubMed listing referenced below. For additional background on CJC-1295, including its research classification and general information, readers can consult the compound overview page.